## **CLAIMS**

## What is claimed:

5

15

25

30

- 1. An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 or the complement of SEQ ID NO: 1.
- 2. The nucleic acid of claim 1 comprising a functional derivative of the nucleotide sequence of SEQ ID. NO: 1.
- 3. The nucleic acid of claim 2 where the functional derivative is selected from the group consisting of a fragment, and a degenerate variant.
- The nucleic acid of claim 3 where the functional derivative is a fragment and the fragment comprises a contiguous sequence of at least 15 nucleotides of SEQ ID NO: 1 or the complement of SEQ ID NO: 1.
  - 5. The nucleic acid of claim 3 where the functional derivative is a fragment and the fragment comprises a contiguous sequence of at least 20 nucleotides of SEQ ID NO: 1 or the complement of SEQ ID NO: 1.
  - 6. The nucleic acid of claim 1 comprising a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 1.
  - 7. The nucleic acid of claim 1 comprising a nucleotide sequence which is at least 80% identical to the nucleotide sequence of SEQ ID NO: 1.
- 20 8. The nucleic acid of claim 1 comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO: 1.
  - 9. The nucleic acid of claim 1 comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO: 1.
  - 10. The nucleic acid of claim 1 where said nucleotide sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 2, a fragment of SEQ ID NO: 2 at least 5 amino acid residue in length, or a degenerate variant of SEQ ID NO: 2.
  - 11. The nucleic acid of claim 1 where said nucleotide sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 2 wherein (a) at position 26 the amino acid cysteine is replaced by serine; (b) at position 44 the amino acid cysteine is replaced by serine; or (c) both (a) and (b).
  - 12. The nucleic acid of claim 1 where said nucleotide sequence encodes a polypeptide the amino acid sequence of which is at least 80% identical to SEQ ID NO: 2.

- 13. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe the nucleotide sequence of which consists of SEQ ID NO: 1, the complement of SEQ ID NO: 1, a fragment of SEQ ID NO: 1 at least 15 nucleotides in length or the complement of a fragment of SEQ ID NO: 1 at least 15 nucleotides in length.
- 14. A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 2, or a degenerate variant of SEQ ID NO: 2.
- 15. The purified polypeptide of claim 14 the amino acid sequence of which comprises a fragment of SEQ ID NO: 2 of at least 5 consecutive amino acids.
- 16. The purified polypeptide of claim 14 the amino acid sequence of which comprises a fragment of SEQ ID NO: 2 of at least 5 consecutive amino acids, wherein said polypeptide is immunologically reactive with an anti-GBS phage lysin antibody.
- 17. The purified polypeptide of claim 14 the amino acid sequence of which is at least 50% identical to SEQ ID NO: 2.
- 18. The purified polypeptide of claim 14 the amino acid sequence of which is at least 80% identical to SEQ ID NO: 2.
- 19. The purified polypeptide of claim 14 the amino acid sequence of which is at least 90% identical to SEO ID NO: 2.
- 20. The purified polypeptide of claim 14 the amino acid sequence of which is at least 95% identical to SEQ ID NO: 2.
  - 21. The purified polypeptide of claim 14 the amino acid sequence of which comprises a fragment of SEQ ID NO: 2 selected from the group consisting of residues 1-107, 6-107, 6-443, 1-344, 145-344, 145-443 and 6-344.
- 25 22. The purified polypeptide of claim 21 where the polypeptide express at least one of an endopeptidase or a glycosidase activity.
  - 23. The purified polypeptide of claim 14 wherein (a) at position 26 the amino acid cysteine is replaced by serine; (b) at position 44 the amino acid cysteine is replaced by serine; or (c) both (a) and (b).
- The purified polypeptide of claim 23 where the polypeptide does not express an endopeptidase activity.

5

10

15

- 25. The purified polypeptide of claim 14 where the polypeptide express an endopeptidase and a glycosidase activity.
- 26. An expression vector comprising the nucleic acid of claim 1 operably linked to an expression control sequence.
- 27. A non-human host cell comprising the expression vector of claim 26.

5

15

20

25

- 28. A method of producing a GBS phage lysin, the method comprising culturing the host cell of claim 27 under conditions permitting expression of the GBS phage lysin from the expression vector.
- 10 29. The method of claim 28 further comprising purifying the GBS phage lysin.
  - 30. A method of treating or preventing a condition caused by a bacteria in an individual in need of such treatment or prevention, the method comprising the step of administering to the individual an effective amount of a therapeutic agent, the therapeutic agent comprising the polypeptide of claim 14 in a pharmaceutically acceptable carrier, said bacteria having a peptidoglycan structure comprising an interpeptide bridge consisting of (L-Ala)<sub>2</sub> or L-Ala-L-Ser.
  - 31. The method of claim 30 where the bacteria is a group B streptococci and the condition is a vaginal colonization of the group B streptococci.
  - 32. The method of claim 31 where the pharmaceutically acceptable carrier is a tampon, pad or a douche.
  - 33. The method of claim 30 where the bacteria are selected from the group consisting of group A streptococci, group B streptococci, group C streptococci, group E streptococci, and group G streptococci.
  - 34. The method claim 30 further comprising the step of administration of a modulating compound in a pharmaceutically acceptable carrier.
  - 35. A method of disrupting the cell walls of a bacteria comprising the step of contacting the bacteria with the protein of claim 14, said bacteria having a peptidoglycan structure comprising an interpeptide bridge comprising (L-Ala)<sub>2</sub> or L-Ala-L-Ser.
- The method of claim 35 where the bacteria are selected from the group consisting of group A streptococci, group B streptococci, group C streptococci, group E streptococci, and group G streptococci.